Myovant Sciences EBITDA 2017-2022 | MYOV

Myovant Sciences ebitda from 2017 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Myovant Sciences Annual EBITDA
(Millions of US $)
2022 $-182
2021 $-258
2020 $-272
2019 $-262
2018 $-140
2017 $-56
2016 $-2
Myovant Sciences Quarterly EBITDA
(Millions of US $)
2022-03-31 $-49
2021-12-31 $-59
2021-09-30 $-18
2021-06-30 $-57
2021-03-31 $-76
2020-12-31 $-78
2020-09-30 $-71
2020-06-30 $-33
2020-03-31 $-64
2019-12-31 $-77
2019-09-30 $-66
2019-06-30 $-64
2019-03-31 $-71
2018-12-31 $-69
2018-09-30 $-64
2018-06-30 $-59
2018-03-31 $-47
2017-12-31 $-41
2017-09-30 $-30
2017-06-30 $-22
2017-03-31 $-23
2016-12-31 $-9
2016-09-30 $-7
2016-06-30 $-17
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.313B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00